AVANIR Invites Investors to Webcast of Pacific Growth Equities Life Sciences Growth Conference Presentation

AVANIR Pharmaceuticals, (AMEX:AVN) today announced that
its presentation at the Pacific Growth Equities Life Sciences Growth
Conference will be webcast live through the Company's web site at
http://www.avanir.com. Vice President and Chief Financial Officer
Gregory P. Hanson will be presenting at 9:30 am Pacific time on June
8th from the conference in San Francisco.
   The live webcast will be accessible through AVANIR's corporate
website via a link on the lower left side of the homepage. To access
the webcast, please log on to AVANIR's site approximately fifteen
minutes prior to the presentation to register and download any
necessary audio software. An archived version of the presentation will
be available for 90 days following the conference.
   AVANIR Pharmaceuticals is a pharmaceutical company focused on
developing and commercializing novel therapeutic products for the
treatment of chronic diseases. AVANIR's product candidates address
therapeutic markets that include central nervous system and
cardiovascular disorders, inflammation, and infectious disease. AVANIR
expects to submit the final module of its rolling new drug application
to the U.S. Food and Drug Administration for its lead product
candidate, Neurodex(TM), in mid-2005. Recently, AVANIR partnered its
preclinical research and development program for inflammatory disease
with Novartis. The Company's first commercialized product, Abreva(R),
is marketed in North America by GlaxoSmithKline Consumer Healthcare
and is the leading over-the-counter product for the treatment of cold
sores. Further information about AVANIR can be found at
www.avanir.com.

   The information contained in this press release, including any
forward-looking statements contained herein, should be reviewed in
conjunction with the company's most recent Annual Report on Form 10-K
and other publicly available information regarding the company. Copies
of such information are available from the company upon request. Such
publicly available information sets forth many risks and uncertainties
related to the company's business and technology. Forward-looking
statements often contain such words like "estimate," "anticipate,"
"believe," "plan" or "expect". Final review decisions made by the FDA
and other regulatory agencies concerning clinical trial results are
unpredictable and outside the influence and/or control of the company.
The Company disclaims any intent or obligation to update these
forward-looking statements.